Haemonetics (HAE) FY2019 results: revenue $968 million, up 7.0% on the year
Haemonetics Corp. (HAE) reported revenue of $968 million for fiscal 2019, the year ended 30 March 2019, up 7.0% on the year before. Net income was $55 million, up 20.7%, and diluted earnings per share $1.04. The figures are the company's own, from the 10-K it filed with the SEC on 22 May 2019.
Revenue
$968 million
+7.0% on the year
FY2012FY2019
Operating margin
8.6%
6.2% a year earlier
FY2012FY2019
Net income
$55 million
+20.7% on the year
FY2012FY2019
Diluted EPS
$1.04
+22.4% on the year
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
968
904
886
+7.0%
Cost of revenue
550
492
508
+11.8%
Gross profit
418
412
378
+1.4%
Gross margin
43.2%
45.6%
42.7%
Research and development
35.7
39.2
37.6
-9.0%
Selling, general and administrative
273
317
302
-13.6%
Operating income
83.5
56.2
-19.4
+48.8%
Operating margin
8.6%
6.2%
-2.2%
Interest expense
12.6
7.7
n/a
+63.6%
Pre-tax income
73.6
59.6
-27.5
+23.5%
Income tax
18.6
14.1
-1.2
+32.4%
Effective tax rate
25.3%
23.6%
n/a
Net income
55.0
45.6
-26.3
+20.7%
Net margin
5.7%
5.0%
-3.0%
Diluted EPS
$1.04
$0.85
-$0.51
+22.4%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
159
220
160
-27.7%
Capital expenditure
119
74.8
76.1
+59.0%
Free cash flow
40.3
146
83.6
-72.3%
Free cash flow margin
4.2%
16.1%
9.4%
Cash from investing
-116
-63.0
-73.3
Cash from financing
-50.6
-121
-60.4
Depreciation and amortisation
109
89.2
89.7
+22.6%
Share-based compensation
17.2
13.0
9.2
+32.0%
Buybacks
160
100
0.0
+60.0%
Diluted shares, weighted
53m
54m
52m
-1.0%
Shares outstanding at period end
51m
52m
52m
-2.5%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
668
752
740
-11.2%
Debt
350
254
316
+38.0%
Other liabilities
257
231
183
+11.1%
Total liabilities and equity
1,275
1,237
1,239
+3.0%
Fixed assets
344
332
324
+3.6%
Goodwill
211
211
211
-0.3%
Intangible assets
128
157
178
-18.5%
Cash and equivalents
169
180
140
-6.0%
Receivables
185
151
153
+22.4%
Inventory
194
161
177
+20.9%
Other assets
43.6
45.0
57.3
-3.2%
Total assets
1,275
1,237
1,239
+3.0%
10-K for the year ended 30 March 2019, filed 22 May 2019: the filing.